Clinical Trials
3 trialsNCT04262466 2026-03-06
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Phase 1/2 Active not recruiting
NCT03973333 2024-10-18
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Immunocore Ltd
Phase 1/2 Withdrawn
NCT03515551 2022-03-11
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
Immunocore Ltd
Phase 1/2 Terminated